Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Dalotuzumab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Dalotuzumab?

Dalotuzumab is an investigational drug.

There have been 13 clinical trials for Dalotuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Alliance for Clinical Trials in Oncology, and National Cancer Institute (NCI).

Recent Clinical Trials for Dalotuzumab
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)Merck Sharp & Dohme Corp.Phase 2
A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)Merck Sharp & Dohme Corp.Phase 2
Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)Merck Sharp & Dohme Corp.Phase 1

See all Dalotuzumab clinical trials

Clinical Trial Summary for Dalotuzumab

Top disease conditions for Dalotuzumab
Top clinical trial sponsors for Dalotuzumab

See all Dalotuzumab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.